Anti-CTLA4 checkpoint inhibitor OV dropped by AstraZeneca
Transgene is focused on early-phase trials of two viruses, one that expresses IL-12 and an anti-CTLA4 antibody and another that encodes an anti-CTLA4 antibody.
Responsibility for overseeing development of those candidates will now fall on Alessandro Riva, M.D., who is set to take over as Transgene CEO at the start of next month.
https://www.fiercebiotech.com/biotech/astrazeneca-scraps-pact-riva-led-transgene-further-blow-oncolytic-viruses
[Today's development between AstraZeneca and Transgene further opens the OV market for ONCY since ONCY has demonstrated that the pelareorep + PD-(L)1 immune checkpoint inhibitors is a synergistic combination due to pelareorep's ablity to stimulate the innate and adaptive immune system and remodel an immunosuppressive and hypoxic tumor microenvironment (TME) in advance of the addition of PD-(L)1 checkpoint inhibition.
Additionally ONCY's pelareorep is potentially synergistic with AstraZeneca's immuno-oncology pipeline involving AstraZeneca's PD-(L)1 immune checkpoint inhibitors (durvalumab), antibody drug conjugates (ADCs)(i.e.Enhertu), PARP and CDK4,6 small molecule inhibitors, CAR-T therapy and CAR-T/TIGIT bispecifics (rilverostomig{AZD2936}Artemide-01).
https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-advances-its-pipeline-and-highlights-progress-in-immuno-oncology-adcs-cell-therapy-and-epigenetics-at-aacr.html